Relationship Between Dosage of Clopidogrel and Platelet Aggregation in Chinese With Different Genotype (RDPAC)

Chinese Academy of Medical Sciences, Fuwai Hospital

Status: Unknown

Conditions: Coronary Heart Disease

Study type: Observational

Funder types: Other

Identifiers

NCT01710436

RDPAC2012

Details and patient eligibility

About

This study is a prospective, observational study to estimate the relationship between dosage of clopidogrel and platelet aggregation in Chinese with different genotype. The investigators suppose both pretreatment dosage of clopidogrel before percutaneous coronary intervention (PCI) and CYP2C19 genotype may effect the platelet aggregation as well as clinical outcome.

Enrollment: 880 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• accept PCI in Chinese CHD patients
• expected dual antiplatelet therapy (DAPT) at least 6 months

Exclusion criteria

• another planned PCI within 6 months

Trial design

880 participants in 4 patient groups

Low dose - Wild genotype (LW)

Description:

75mg Qd \> 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 wild genotype

Low dose - Variant genotype (LV)

Description:

75mg Qd \> 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 variant genotype

High dose - Wild genotype (HW)

Description:

300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 wild genotype

High dose - Variant genotype (HV)

Description:

300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 variant genotype